Back To Index << Back To Terminology

# Value Set eHDSIActiveIngredient 2020‑04‑23 15:10:00

This terminology is a snapshot as of 2026‑02‑11 10:48:51. Terminologies may evolve over time. If you need recent (dynamic) versions of this terminology, please retrieve it from the source.
Id | 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 | Effective Date | 2020‑04‑23 15:10:00 Other versions this id: eHDSIActiveIngredient202602 - as of 2026‑02‑06 15:15:00 eHDSIActiveIngredient202502 - as of 2025‑02‑17 15:15:00 eHDSIActiveIngredient202401 - as of 2024‑01‑25 16:10:00 eHDSIActiveIngredient202301 - as of 2023‑01‑17 16:05:00 eHDSIActiveIngredient202201 - as of 2022‑01‑31 16:00:00 eHDSIActiveIngredient202104 - as of 2021‑04‑19 15:45:00 eHDSIActiveIngredient202006 - as of 2020‑06‑17 11:51:00 epSOSActiveIngredient201912 - as of 2019‑12‑23 16:20:21 epSOSActiveIngredient201711 - as of 2017‑11‑07 14:06:21 epSOSActiveIngredientJanuary 2010 - as of 2013‑06‑03
Status | Deprecated | Version Label | 202004
Name | eHDSIActiveIngredient | Display Name | eHDSIActiveIngredient
Description
The Value Set is used as a mandatory code for the Active Ingredient of medications in the Medications Summary as well as the prescription Sections. Also used to code allergy agents in the Allergies and Other Adverse Reactions Section of the patient Summary.
Source Code System | 2.16.840.1.113883.6.73 - WHO Anatomical Therapeutic Chemical classification - FHIR: http://www.whocc.no/atc - HL7 V2: WC
Level/ Type | Code | Display Name | Code System
--- | --- | --- | ---
0‑L | A | ALIMENTARY TRACT AND METABOLISM | WHO Anatomical Therapeutic Chemical classification
0‑L | A01 | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification
0‑L | A01A | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA | Caries prophylactic agents | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA01 | sodium fluoride | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA02 | sodium monofluorophosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA03 | olaflur | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA04 | stannous fluoride | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA30 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA51 | sodium fluoride, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB | Antiinfectives and antiseptics for local oral treatment | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB02 | hydrogen peroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB03 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB04 | amphotericin B | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB05 | polynoxylin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB06 | domiphen | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB07 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB08 | neomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB09 | miconazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB10 | natamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB11 | various | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB12 | hexetidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB13 | tetracycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB14 | benzoxonium chloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB15 | tibezonium iodide | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB16 | mepartricin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB17 | metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB18 | clotrimazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB19 | sodium perborate | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB21 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB22 | doxycycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB23 | minocycline | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC | Corticosteroids for local oral treatment | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC01 | triamcinolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC02 | dexamethasone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC03 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC54 | prednisolone, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD | Other agents for local oral treatment | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD01 | epinephrine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD02 | benzydamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD05 | acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD06 | adrenalone | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD07 | amlexanox | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD08 | becaplermin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD11 | various | WHO Anatomical Therapeutic Chemical classification
0‑L | A02 | DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A02A | ANTACIDS | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA | Magnesium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA04 | magnesium hydroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA05 | magnesium silicate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA10 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB | Aluminium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB01 | aluminium hydroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB02 | algeldrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB03 | aluminium phosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB04 | dihydroxialumini sodium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB05 | aluminium acetoacetate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB06 | aloglutamol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB07 | aluminium glycinate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB10 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC | Calcium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC01 | calcium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC02 | calcium silicate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC10 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD | Combinations and complexes of aluminium, calcium and magnesium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD01 | ordinary salt combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD02 | magaldrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD03 | almagate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD04 | hydrotalcite | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD05 | almasilate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF | Antacids with antiflatulents | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF01 | magaldrate and antiflatulents | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF02 | ordinary salt combinations and antiflatulents | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AG | Antacids with antispasmodics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AH | Antacids with sodium bicarbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AX | Antacids, other combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA | H2-receptor antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA01 | cimetidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA02 | ranitidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA03 | famotidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA04 | nizatidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA05 | niperotidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA06 | roxatidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA07 | ranitidine bismuth citrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA08 | lafutidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA51 | cimetidine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA53 | famotidine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB | Prostaglandins | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB01 | misoprostol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB02 | enprostil | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC | Proton pump inhibitors | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC01 | omeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC02 | pantoprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC03 | lansoprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC04 | rabeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC05 | esomeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC06 | dexlansoprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC07 | dexrabeprazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC53 | lansoprazole, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC54 | rabeprazole, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD | Combinations for eradication of Helicobacter pylori | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD01 | omeprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD02 | lansoprazole, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD03 | lansoprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD04 | pantoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD05 | omeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD06 | esomeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD07 | lansoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD08 | bismuth subcitrate, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD09 | lansoprazole, clarithromycin and tinidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD10 | lansoprazole, amoxicillin and levofloxacin | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD11 | pantoprazole, amoxicillin, clarithromycin and metronidazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX01 | carbenoxolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX02 | sucralfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX03 | pirenzepine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX04 | methiosulfonium chloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX05 | bismuth subcitrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX06 | proglumide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX07 | gefarnate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX08 | sulglicotide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX09 | acetoxolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX10 | zolimidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX11 | troxipide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX12 | bismuth subnitrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX13 | alginic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX14 | rebamipide | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX51 | carbenoxolone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX71 | carbenoxolone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX77 | gefarnate, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A02X | OTHER DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03 | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03A | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA | Synthetic anticholinergics, esters with tertiary amino group | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA01 | oxyphencyclimine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA03 | camylofin | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA04 | mebeverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA05 | trimebutine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA06 | rociverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA07 | dicycloverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA08 | dihexyverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA09 | difemerine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA30 | piperidolate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB | Synthetic anticholinergics, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB01 | benzilone | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB02 | glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB03 | oxyphenonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB04 | penthienate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB05 | propantheline | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB06 | otilonium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB07 | methantheline | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB08 | tridihexethyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB09 | isopropamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB10 | hexocyclium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB11 | poldine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB12 | mepenzolate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB13 | bevonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB14 | pipenzolate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB15 | diphemanil | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB16 | (2-benzhydryloxyethyl)diethyl-methylammonium iodide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB17 | tiemonium iodide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB18 | prifinium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB19 | timepidium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB21 | fenpiverinium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB53 | oxyphenonium, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC | Synthetic antispasmodics, amides with tertiary amines | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC02 | dimethylaminopropionylphenothiazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC04 | nicofetamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC05 | tiropramide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD | Papaverine and derivatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD01 | papaverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD02 | drotaverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD30 | moxaverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE | Serotonin receptor antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE01 | alosetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE03 | cilansetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX | Other drugs for functional gastrointestinal disorders | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX01 | fenpiprane | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX02 | diisopromine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX03 | chlorbenzoxamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX04 | pinaverium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX05 | fenoverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX06 | idanpramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX07 | proxazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX08 | alverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX09 | trepibutone | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX10 | isometheptene | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX11 | caroverine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX12 | phloroglucinol | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX13 | silicones | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX14 | valethamate | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX30 | trimethyldiphenylpropylamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX58 | alverine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A03B | BELLADONNA AND DERIVATIVES, PLAIN | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA | Belladonna alkaloids, tertiary amines | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA01 | atropine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA03 | hyoscyamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA04 | belladonna total alkaloids | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB01 | butylscopolamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB02 | methylatropine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB03 | methylscopolamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB04 | fentonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB05 | cimetropium bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03C | ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA | Synthetic anticholinergic agents in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA01 | isopropamide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA02 | clidinium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA03 | oxyphencyclimine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA04 | otilonium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA05 | glycopyrronium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA06 | bevonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA07 | ambutonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA08 | diphemanil and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA09 | pipenzolate and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA30 | emepronium and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA34 | propantheline and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB | Belladonna and derivatives in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB01 | methylscopolamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB02 | belladonna total alkaloids and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB03 | atropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB04 | methylhomatropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB31 | hyoscyamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CC | Other antispasmodics in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03D | ANTISPASMODICS IN COMBINATION WITH ANALGESICS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA | Synthetic anticholinergic agents in combination with analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA01 | tropenzilone and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA02 | pitofenone and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA03 | bevonium and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA04 | ciclonium and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA05 | camylofin and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA06 | trospium and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA07 | tiemonium iodide and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DB | Belladonna and derivatives in combination with analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DB04 | butylscopolamine and analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DC | Other antispasmodics in combination with analgesics | WHO Anatomical Therapeutic Chemical classification
0‑L | A03E | ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS | WHO Anatomical Therapeutic Chemical classification
0‑L | A03EA | Antispasmodics, psycholeptics and analgesics in combination | WHO Anatomical Therapeutic Chemical classification
0‑L | A03ED | Antispasmodics in combination with other drugs | WHO Anatomical Therapeutic Chemical classification
0‑L | A03F | PROPULSIVES | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA | Propulsives | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA01 | metoclopramide | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA02 | cisapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA03 | domperidone | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA04 | bromopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA05 | alizapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA06 | clebopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA07 | itopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA08 | cinitapride | WHO Anatomical Therapeutic Chemical classification
0‑L | A04 | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A04A | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA | Serotonin (5HT3) antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA01 | ondansetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA02 | granisetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA03 | tropisetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA04 | dolasetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA05 | palonosetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA55 | palonosetron, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD | Other antiemetics | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD01 | scopolamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD02 | cerium oxalate | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD04 | chlorobutanol | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD05 | metopimazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD10 | dronabinol | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD11 | nabilone | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD12 | aprepitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD13 | casopitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD14 | rolapitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD51 | scopolamine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD54 | chlorobutanol, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A05 | BILE AND LIVER THERAPY | WHO Anatomical Therapeutic Chemical classification
0‑L | A05A | BILE THERAPY | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA | Bile acids and derivatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA01 | chenodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA02 | ursodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA03 | cholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA04 | obeticholic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AB | Preparations for biliary tract therapy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AB01 | nicotinyl methylamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX | Other drugs for bile therapy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX01 | piprozolin | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX02 | hymecromone | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX03 | cyclobutyrol | WHO Anatomical Therapeutic Chemical classification
0‑L | A05B | LIVER THERAPY, LIPOTROPICS | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA | Liver therapy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA01 | arginine glutamate | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA03 | silymarin | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA04 | citiolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA05 | epomediol | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA06 | ornithine oxoglurate | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA07 | tidiacic arginine | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA08 | glycyrrhizic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05C | DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification
0‑L | A06 | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification
0‑L | A06A | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA | Softeners, emollients | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA01 | liquid paraffin | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA02 | docusate sodium | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA51 | liquid paraffin, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB | Contact laxatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB01 | oxyphenisatine | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB03 | dantron | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB04 | phenolphthalein | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB05 | castor oil | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB06 | senna glycosides | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB07 | cascara | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB08 | sodium picosulfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB09 | bisoxatin | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB20 | contact laxatives in combination | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB30 | contact laxatives in combination with belladonna alkaloids | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB52 | bisacodyl, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB53 | dantron, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB56 | senna glycosides, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB57 | cascara, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB58 | sodium picosulfate, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC | Bulk-forming laxatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC01 | ispaghula (psylla seeds) | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC02 | ethulose | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC03 | sterculia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC05 | linseed | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC06 | methylcellulose | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC07 | triticum (wheat fibre) | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC08 | polycarbophil calcium | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC51 | ispaghula, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC53 | sterculia, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC55 | linseed, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD | Osmotically acting laxatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD04 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD10 | mineral salts in combination | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD11 | lactulose | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD12 | lactitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD13 | sodium sulfate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD14 | pentaerithrityl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD15 | macrogol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD16 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD17 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD18 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD19 | magnesium citrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD21 | sodium tartrate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD61 | lactulose, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD65 | macrogol, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG | Enemas | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG01 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG03 | dantron, incl. combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG04 | glycerol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG06 | oil | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG07 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG10 | docusate sodium, incl. combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG11 | sodium lauryl sulfoacetate, incl. combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG20 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH | Peripheral opioid receptor antagonists | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH01 | methylnaltrexone bromide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH02 | alvimopan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH03 | naloxegol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH04 | naloxone | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH05 | naldemedine | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX | Other drugs for constipation | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX01 | glycerol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX02 | carbon dioxide producing drugs | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX03 | lubiprostone | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX04 | linaclotide | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX05 | prucalopride | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX06 | tegaserod | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX07 | plecanatide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07 | ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07A | INTESTINAL ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA01 | neomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA02 | nystatin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA03 | natamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA04 | streptomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA05 | polymyxin B | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA06 | paromomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA07 | amphotericin B | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA08 | kanamycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA09 | vancomycin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA10 | colistin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA11 | rifaximin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA12 | fidaxomicin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA51 | neomycin, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA54 | streptomycin, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB | Sulfonamides | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB02 | phthalylsulfathiazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB03 | sulfaguanidine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB04 | succinylsulfathiazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AC | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AC01 | miconazole | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX | Other intestinal antiinfectives | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX01 | broxyquinoline | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX02 | acetarsol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX03 | nifuroxazide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX04 | nifurzide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07B | INTESTINAL ADSORBENTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA | Charcoal preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA01 | medicinal charcoal | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA51 | medicinal charcoal, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BB | Bismuth preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC | Other intestinal adsorbents | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC01 | pectin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC02 | kaolin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC03 | crospovidone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC04 | attapulgite | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC05 | diosmectite | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC30 | combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC54 | attapulgite, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07C | ELECTROLYTES WITH CARBOHYDRATES | WHO Anatomical Therapeutic Chemical classification
0‑L | A07CA | Oral rehydration salt formulations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07D | ANTIPROPULSIVES | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA | Antipropulsives | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA01 | diphenoxylate | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA02 | opium | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA03 | loperamide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA04 | difenoxin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA05 | loperamide oxide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA06 | eluxadoline | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA52 | morphine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA53 | loperamide, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07E | INTESTINAL ANTIINFLAMMATORY AGENTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA | Corticosteroids acting locally | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA01 | prednisolone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA02 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA03 | prednisone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA04 | betamethasone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA05 | tixocortol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA06 | budesonide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA07 | beclometasone | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EB | Antiallergic agents, excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EB01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC | Aminosalicylic acid and similar agents | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC01 | sulfasalazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC02 | mesalazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC03 | olsalazine | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC04 | balsalazide | WHO Anatomical Therapeutic Chemical classification
0‑L | A07F | ANTIDIARRHEAL MICROORGANISMS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA | Antidiarrheal microorganisms | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA01 | lactic acid producing organisms | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA02 | saccharomyces boulardii | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA51 | lactic acid producing organisms, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A07X | OTHER ANTIDIARRHEALS | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA | Other antidiarrheals | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA01 | albumin tannate | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA02 | ceratonia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA03 | calcium compounds | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA04 | racecadotril | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA06 | crofelemer | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA51 | albumin tannate, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A08 | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A08A | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA | Centrally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA01 | phentermine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA02 | fenfluramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA03 | amfepramone | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA04 | dexfenfluramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA05 | mazindol | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA06 | etilamfetamine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA07 | cathine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA08 | clobenzorex | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA09 | mefenorex | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA10 | sibutramine | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA11 | lorcaserin | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA56 | ephedrine, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA62 | bupropion and naltrexone | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AB | Peripherally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AB01 | orlistat | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AX | Other antiobesity drugs | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AX01 | rimonabant | WHO Anatomical Therapeutic Chemical classification
0‑L | A09 | DIGESTIVES, INCL. ENZYMES | WHO Anatomical Therapeutic Chemical classification
0‑L | A09A | DIGESTIVES, INCL. ENZYMES | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA | Enzyme preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA01 | diastase | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA02 | multienzymes (lipase, protease etc.) | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA03 | pepsin | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA04 | tilactase | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB | Acid preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB01 | glutamic acid hydrochloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB02 | betaine hydrochloride | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB03 | hydrochloric acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB04 | citric acid | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AC | Enzyme and acid preparations, combinations | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AC01 | pepsin and acid preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AC02 | multienzymes and acid preparations | WHO Anatomical Therapeutic Chemical classification
0‑L | A10 | DRUGS USED IN DIABETES | WHO Anatomical Therapeutic Chemical classification
0‑L | A10A | INSULINS AND ANALOGUES | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB | Insulins and analogues for injection, fast-acting | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB03 | insulin (pork) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB04 | insulin lispro | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB05 | insulin aspart | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB06 | insulin glulisine | WHO Anatomical Therapeutic Chemical classification
This value set has 6231 codes in it. In order to keep the publication size manageable, only a selection (500 codes) of the whole set of codes is shown.
Legenda: Type L=leaf, S=specializable, A=abstract, D=deprecated. NullFlavor OTH (other) suggests text in originalText. HL7 V3: NullFlavors to appear in @nullFlavor attribute instead of @code.
| XML JSON CSV SQL SVS FHIR (4.0) [xml / json]